Lab
PRG Technologies, INC
PRG Technologies, INC was paid $5.85M by Medicaid between Sep 2021 and Nov 2024, across 6 billing codes. Its largest line is 87637, Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV — 90% of everything it billed.
33Billing provider infoPRG TECHNOLOGIES, INC
ANAHEIM, CA 92805
ANAHEIM, CA 92805
33aNPI1568133411assigned 09/21/2021
33bProvider typeClinical Medical Laboratory
28Total paid$5.85M
24GClaims53,324
24DCodes billed6
24AFirst – last monthSep 2021 – Nov 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#101 of 561
Median peer was paid$222K
This provider vs. median26×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 1,453 | $54K | |
| 2022 | 7,841 | $428K | |
| 2023 | 14,765 | $1.72M | |
| 2024incomplete | 29,265 | $3.64M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 90% | 39,709 | 19,653 | $5.28M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 5.2% | 4,483 | 3,254 | $305K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.3% | 4,193 | 1,825 | $137K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,125 | 1,072 | $48K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,122 | 1,406 | $45K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 692 | 300 | $35K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBASEER, AHSAN (TECHNICAL CONSULTANT)
| Provider | Location | Paid |
|---|---|---|
| Nbio Lab INC | Burbank, CA | $78K |
| Biomed Lab | Glendale, CA | $50K |
| Tekotest Lab INC | Burbank, CA | $48K |
| L&G Laboratory INC | Van Nuys, CA | $12K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.